玮俊生物科技(00660.HK)预期年度净亏损同比大幅收窄
Group 1 - The company expects to record a net loss of no more than HKD 13 million for the fiscal year ending June 30, 2025, which represents a significant reduction compared to a net loss of approximately HKD 65.7 million for the fiscal year ending June 30, 2024 [1] - The substantial decrease in loss is primarily attributed to a reduction in impairment losses on non-financial assets during the reporting year [1]